The COVID-19 pandemic and the global health emergency focused it on the search for safe and effective treatments and vaccines to prevent the new virus. And also, almost as an unwanted effect, has postponed important vaccine research, such as the search for a vaccine against respiratory syncytial virus (RSV), which causes bronchiolitis in newborns, and bilateral pneumonia that can be severe in older adults.
Now, when the situation allows science to take its eyes off the urgency, research that has been postponed for the time being is put back on the lab counter.
and without a doubt, One of medicine’s great debts is finding a vaccine capable of preventing RSV infection, the respiratory disease that causes more newborn hospitalizations in the world and which causes the most viral pneumonia in history, chronic adults with a high mortality rate.
There are three worldwide studies for an RSV vaccine in healthy adults aged 18 to 85 years and in healthy pregnant women aged 18 to 49.
More than 2,000 healthy adults between the ages of 18 and 85 have already been vaccinated with the vaccine, which is in Phase III with the creation of the Pfizer laboratory. “With a very encouraging safety profile”, According to Infobae, a doctor specializing in internal medicine and pulmonologist Alexis Dorsky (MN 141,740) is the principal investigator in the trial taking place at the Fundación Respirar.
about this Renoir Studio, global, randomized, double-blind and placebo-controlled, which the laboratory presented in New York in September and in which Expects to enroll approximately 30,000 participants aged 60 and over.
This work includes two other investigations in Argentina: one has been developed. central military hospital and pediatrician Gonzalo Pérez is in charge of Marc, while the third is directed by researcher Conrado Lapure, At the Mayo Clinic in Tucumán Prefecture.
“It is a vaccine showing a very good safety profile, even in pregnant women in the third trimester, to whom it will be applied with the intention of achieving vertical immunization of newborns, that is, the birth of infants.” Protects against bronchiolitisDetailed Doresky, who stressed that the study of this vaccine is “one of many important things that were suspended because of the urgency of the pandemic.” “This is an unsatisfied public health need that is being raised again,” he insisted.
When asked who is most severely affected by the disease, Doresky stressed that “It affects two extremes of life, newborns and young children and older adults.” “The two extremes of life are when the respiratory tract is at greatest susceptibility, and syncytial virus causes severe bilateral pneumonia that may require hospitalization and respiratory support in older adults with risk factors,” says pulmonologist explained: “Since the 1950s, respiratory syncytial virus has been isolated, and since that moment science has not found a solution. Natural immunity is very short-lived, which is why a large number of pharmaceutical companies have been looking for solutions for this public health problem for years with antivirals or vaccines.,
and after making sure “If COVID is not taken into account, syncytial virus is the first cause of pneumonia of viral origin in older adults”Doresky emphasized that “particularly patients with respiratory diseases such as COPD or asthma or cardiovascular diseases such as heart disease are particularly susceptible and at high risk of developing severe pneumonia caused by this virus.”
“Many times children bring viruses from the garden and infect their grandparents, which is why it is so important to have specific vaccines and antiviral treatments for these two populations.”, I believe
About how RSV infects and the vaccine mechanism
There are two major proteins on the surface of the RSV virus. “If we take these proteins as ‘tags’ as well as the spike protein covering SARS-CoV-2 on its surface, then these surface proteins of RSV are called G and F,” Dorsky explained. . g protein Seeks out filaments (cilia) in the airway to adhere. And once it adheres to our airway, the F or fusion protein attaches to one of our cells and begins its replication or copying of the virus”.
“This Protein F With some structural changes due to its incorporation into a human cell, the virus changes its structure from a prefusion protein to a post-fusion protein”, continued the pulmonologist, who specified: “This protein acts as an antigen”. (something that makes up our immune system and produces antibodies) and G proteins can also act as antigens or primers for our immune system.
Prefusion F subunit vaccines, such as those being studied in-country from the Pfizer laboratory, “use this structure prior to binding with a human cell and show a high safety profile so far.”
Those interested in participating in the study visit the vsr.com.ar page. You can find out and register on